Ole Isacson

33.0k citations

295 papers · 25.2k indexed · 4 hit papers · h-index 89

Impact in

Developmental Neuroscience top 0.01%
- Neurogenesis and neuroplasticity mechanisms
Cellular and Molecular Neuroscience top 0.02%
- Nerve injury and regeneration
- Nuclear Receptors and Signaling
- Neuroscience and Neuropharmacology Research

Papers in

Developmental Neuroscience 77
- Neurogenesis and neuroplasticity mechanisms 73
Cellular and Molecular Neuroscience 194
- Nerve injury and regeneration 88
- Neuroscience and Neuropharmacology Research 45
- Genetic Neurodegenerative Diseases 37
- Nuclear Receptors and Signaling 36

Co-authors: Anders Björklund Penelope J. Hallett Kai‐Christian Sonntag Oliver Cooper Terrence W. Deacon Kevin St. P. McNaught Rosario Sánchez‐Pernaute Patrik Brundin
Journals: Experimental Neurology (25 papers)Neuroscience (17 papers)Stem Cells (16 papers)Progress in brain research (12 papers)Proceedings of the National Academy of Sciences (12 papers)
Partner nations: United States United Kingdom Sweden

In The Last Decade

Ole Isacson

293 papers receiving 24.7k citations

Hit Papers

align trajectories log scale

Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors 2009 · 1.1k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2009 Cell
2008 Proceedings of the National Academy of Sciences
2005 Stem Cells
2002 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Ole Isacson

Since Specialization

Citations

This map shows the geographic impact of Ole Isacson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ole Isacson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ole Isacson more than expected).

Fields of papers citing papers by Ole Isacson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ole Isacson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ole Isacson. The network helps show where Ole Isacson may publish in the future.

Co-authors

The 25 scholars most cited alongside Ole Isacson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ole Isacson Line = papers co-authored together Ole Isacson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Investigating the ATN (Amyloid, Tau, Neurodegeneration) framework in Alzheimer’s Disease and its causal genetic‐drivers using Digital‐Twins Alzheimer s & Dementia ·Andrea Lizeth Montoya Amaya, Kalyan, Carolina Montobbio, Ole Isacson, Ayoub Jannani, Jeanne C. Latourelle	2024	0
2	Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model ofGBA1-associated Parkinson’s disease Human Molecular Genetics ·Manoj Kumar, Tianlei Ma, Michela Deleidi, Penelope J. Hallett, Ole Isacson, Ricardo A. Feldman	2023	9
3	Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease Molecular Neurodegeneration ·Mylene Huebecker, Elizabeth B. Moloney, Aarnoud C. van der Spoel, David A. Priestman, Ole Isacson, Penelope J. Hallett, Frances M. Platt	2019	126
4	Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson’s Disease Molecular Neurobiology ·Xin Wang, Nuomin Li, Nian Xiong, Qi Sheng You, Jie Li, Jinlong Yu, Hong Qing, Tao Wang, Heather J. Cordell, Ole Isacson, Jeffery M. Vance, Eden R. Martin, Ying Zhao, Bruce M. Cohen, Edgar Büttner, Zhicheng Lin	2016	23
5	Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice Antioxidants and Redox Signaling ·Emily M. Rocha, Gaynor A. Smith, Eric Park, Hongmei Cao, Gabriel Matías Lorenz, Tatiana Nascimento Monteiro, Jesse R. McLean, Melissa A. Hayes, Jonathan A. Beagan, Sarah C. Izen, Eduardo Pérez-Torres, Penelope J. Hallett, Ole Isacson	2015	117
6	The Toll-Like Receptor-3 Agonist Polyinosinic:Polycytidylic Acid Triggers Nigrostriatal Dopaminergic Degeneration Journal of Neuroscience ·Michela Deleidi, Penelope J. Hallett, James B. Koprich, Muhammad Ma'mur, Ole Isacson	2010	91
7	Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy Journal of Neuroscience ·Chee Yeun Chung, James B. Koprich, Hasan K. Siddiqi, Ole Isacson	2009	317
8	Recent advances in cell-based therapy for Parkinson disease Neurosurgical FOCUS ·Arnar Astradsson, Oliver Cooper, Ángel Viñuela, Ole Isacson	2008	30
9	An Endogenous Serine/Threonine Protein Phosphatase Inhibitor, G-Substrate, Reduces Vulnerability in Models of Parkinson's Disease Journal of Neuroscience ·Chee Yeun Chung, James B. Koprich, Shogo Endo, Ole Isacson	2007	31
10	What are the long-term effects of neural grafting in patients with Huntington's disease? Nature Clinical Practice Neurology ·Ole Isacson	2006	3
11	Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. Journal of Neuroinflammation ·Rosario Sánchez‐Pernaute, Andrew Ferree, Oliver Cooper, Meixiang Yu, Anna‐Liisa Brownell, Ole Isacson	2004	166
12	Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells Annals of Neurology ·Ole Isacson, 輝雄池田, James M. Schumacher	2003	100
13	Proteasome inhibition causes nigral degeneration with inclusion bodies in rats Neuroreport ·Kevin St. P. McNaught, Kim A. Bolton, Roger Belizaire, Ole Isacson, Peter Jenner, C. Warren Olanow	2002	211
14	Factors intrinsic to the neuron can induce and maintain its ability to promote axonal outgrowth: a role for BCL2? Trends in Neurosciences ·Karin Holm, Ole Isacson	1999	41
15	Therapeutic strategies for Huntington's disease based on a molecular understanding of the disorder Molecular Medicine Today ·Nadia Haque, Paul R. Borghesani, Ole Isacson	1997	18
16	Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions Neuroreport ·David M. Frim, Claudia Mateo, M. Priscilla Short, R.A.J. Janssen, Michael Klagsbrun, X. O. Breakefield, Ole Isacson	1993	151
17	Authentic and artifactual detection of the E. coli lacZ gene product in the rat brain by histochemical methods Molecular Brain Research ·William S. Rosenberg, Xandra O. Breakefield, Fernando Vázquez Pineda, Ole Isacson	1992	29
18	Survival and function of dissociated rat dopamine neurones grafted at different developmental stages or after being cultured in vitro Developmental Brain Research ·Patrik Brundin, G. Barbin, Robert E. Strecker, Ole Isacson, Alain Prochiantz, Anders Björklund	1988	156
19	Neural grafting in a rat model of huntington's disease: Striosomal-like organization of striatal grafts as revealed by acetylcholinesterase histochemistry, immunocytochemistry and receptor autoradiography Neuroscience ·Ole Isacson, D. Dawbarn, P. Brundin, Fred H. Gage, P.C. Emson, Anders Björklund	1987	127
20	CHOLECYSTOKININ CONTENT IN THE BASAL GANGLIA IN HUNTINGTONS-DISEASE - THE EXPRESSION OF CHOLECYSTOKININ IMMUNOREACTIVITY IN STRIATAL GRAFTS TO IBOTENIC ACID-LESIONED RAT STRIATUM UCL Discovery (University College London) ·P.C. Emson, D. Dawbarn, Martin N. Rossor, Rehfeld Jf, P. Brundin, Ole Isacson, Anders Björklund	1985	1

About Ole Isacson

Ole Isacson is a scholar working on Developmental Neuroscience, Cellular and Molecular Neuroscience, Neurology, Neurology and Molecular Biology, having authored 295 papers that have together received 25.2k indexed citations. Recurring topics across this work include Nerve injury and regeneration (88 papers), Neurogenesis and neuroplasticity mechanisms (73 papers), Parkinson's Disease Mechanisms and Treatments (69 papers), Pluripotent Stem Cells Research (66 papers), Neuroscience and Neuropharmacology Research (45 papers), Neurological disorders and treatments (43 papers), Genetic Neurodegenerative Diseases (37 papers) and Nuclear Receptors and Signaling (36 papers). The work is most often cited by research in Developmental Neuroscience (5.3k citations), Cellular and Molecular Neuroscience (13.4k citations), Neurology (7.0k citations), Neurology (2.3k citations) and Molecular Biology (13.3k citations). Ole Isacson has collaborated with scholars based in United States, United Kingdom and Sweden. Frequent co-authors include Anders Björklund, Penelope J. Hallett, Kai‐Christian Sonntag, Oliver Cooper, Terrence W. Deacon, Kevin St. P. McNaught, Rosario Sánchez‐Pernaute, Patrik Brundin, Jan Pruszak and C. Warren Olanow. Their work appears in journals such as Experimental Neurology, Neuroscience, Stem Cells, Progress in brain research and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact